LGALS3 Antibody / Galectin 3 / GAL3, 100 ug

LGALS3 antibody detects Galectin-3, a beta-galactoside-binding lectin involved in cell adhesion, immune modulation, apoptosis regulation, fibrosis, and tumor progression. Galectin-3 functions as both an intracellular regulator and an extracellular signaling molecule, mediating diverse processes such as inflammation, angiogenesis, and cell-matrix interaction. The LGALS3 antibody is extensively used in studies of cancer, cardiovascular disease, and immune disorders where Galectin-3 serves as a biomarker and functional effector in pathological remodeling.

Galectin-3 is encoded by the LGALS3 gene located on human chromosome 14q22.3. The protein contains a carbohydrate recognition domain that binds beta-galactoside residues on glycoproteins and an N-terminal domain enabling oligomerization. This structure allows Galectin-3 to form lattices at the cell surface, influencing receptor clustering and signaling. It is expressed in epithelial cells, macrophages, fibroblasts, and endothelial cells, and can be secreted via a non-classical pathway into the extracellular space. Once outside the cell, it modulates adhesion and migration, contributing to wound healing and fibrosis.

The LGALS3 antibody is particularly useful for detecting Galectin-3 expression in tumor and fibrotic tissues. Western blot typically shows an ~26 kilodalton band, while immunostaining reveals cytoplasmic, nuclear, or membrane-associated localization depending on cellular context. Overexpression of Galectin-3 is associated with aggressive tumor phenotypes, including resistance to apoptosis and enhanced metastasis. Mechanistically, Galectin-3 interacts with cell-surface receptors such as integrins and growth factor receptors, amplifying signaling through the phosphoinositide 3-kinase/AKT and transforming growth factor beta (TGF-beta) pathways. This dual role in intracellular survival signaling and extracellular communication underscores its complexity as a therapeutic target.

Beyond oncology, Galectin-3 contributes to fibrotic progression in the heart, kidneys, and liver. It promotes fibroblast activation, collagen deposition, and tissue stiffening, leading to organ dysfunction. Elevated plasma Galectin-3 levels are now used clinically as a prognostic biomarker for heart failure. In immune regulation, Galectin-3 modulates macrophage polarization, promotes neutrophil adhesion, and suppresses T-cell receptor signaling, linking innate and adaptive immune responses. NSJ Bioreagents offers a validated LGALS3 antibody optimized for western blot, ELISA, flow cytometry, and immunohistochemistry, providing reliable detection of Galectin-3 for applications across cancer, inflammation, and fibrotic disease research.